The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ATRA | +23.78% | -97.7% | -52.95% | -95% |
| S&P | +12.26% | +86.71% | +13.3% | +252% |
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Investors were hoping for more from the company's latest clinical update.
A fatality in an early-stage clinical trial is weighing on the cell therapy company's stock today.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.45M | -91.4% |
| Gross Profit | $3.34M | -89.8% |
| Gross Margin | 96.67% | 15.6% |
| Market Cap | $100.64M | 118.2% |
| Market Cap / Employee | $0.66M | 0.0% |
| Employees | 153 | -32.0% |
| Net Income | -$4.30M | 80.4% |
| EBITDA | -$3.51M | 82.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.74M | -87.7% |
| Accounts Receivable | $1.91M | 43.3% |
| Inventory | 0 | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $46.98M | -35.5% |
| Short Term Debt | $11.62M | -23.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 27.07% | 107.4% |
| Return On Invested Capital | 106.17% | 82.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.79M | -145.3% |
| Operating Free Cash Flow | -$9.79M | -145.3% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 6.54 | - | |||
| Price to Book | -0.84 | -0.36 | -0.83 | -2.85 | 693.55% |
| Price to Sales | 1.10 | 0.32 | 0.50 | 1.28 | 111.70% |
| Price to Tangible Book Value | -0.84 | -0.36 | -0.83 | -2.85 | 693.55% |
| Enterprise Value to EBITDA | -15.70 | 2.60 | 26.47 | -68.15 | 1617.64% |
| Return on Equity | -2014.9% | - | |||
| Total Debt | $84.06M | $80.50M | $58.46M | $58.60M | -33.46% |
No podcast episodes available.
ATRA earnings call for the period ending September 30, 2021.
ATRA earnings call for the period ending June 30, 2021.
ATRA earnings call for the period ending March 31, 2021.
ATRA earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
